SCHEMBL28901979

SCHEMBL28901979

O=S(=O)(c1ccccc1)n1ccc(Cl)c1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
MET P08581 1/20 0.41
CYP2C19 P33261 1/20 0.41
PKM P14618 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RECQL P46063 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421682 0.72 HTR6 (0.47) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL4830073 0.71 HTR6 (0.46) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL28282196 0.70 HTR6 (0.45) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL14375312 0.69 HTR6 (0.47) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL2432960 0.69 HTR6 (0.64) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL18555846 0.69 HTR6 (0.44) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL16097068 0.69 HTR6 (0.44) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL28189646 0.68 HTR6 (0.50) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL16824206 0.68 MET (0.42) HTR6ALDH1A1LMNAHTTMEN1
SCHEMBL29713714 0.68 CYP2C19 (0.45) HTR6ALDH1A1LMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398141-B2 JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) 2025-08-26 US disclosed
US-20220185816-A1 JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) 2022-06-16 US disclosed
CN-106866658-B 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors 沃纳利斯(R&D)有限公司 2021-04-27 CN disclosed
CN-111484493-A 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors 沃纳利斯(R&D)有限公司 2020-08-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398141-B2 JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine JAK1, JAK2, JAK3 HTR6 4345/4885ALDH1A1 2619/4885LMNA 4608/4885
US-20220185816-A1 JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE JAK1, JAK2, JAK3 HTR6 4345/4885ALDH1A1 2619/4885LMNA 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.